Prinoxodan
- Product Name
- Prinoxodan
- CAS No.
- 111786-07-3
- Chemical Name
- Prinoxodan
- Synonyms
- RGW2938;Prinoxodan;Prinoxodan (RGW2938);3-Methyl-6-(6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)-3,4-dihydroquinazolin-2(1H)-one;2(1H)-Quinazolinone, 3,4-dihydro-3-methyl-6-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-
- CBNumber
- CB81118261
- Molecular Formula
- C13H14N4O2
- Formula Weight
- 258.28
- MOL File
- 111786-07-3.mol
Prinoxodan Property
- Melting point:
- >250 °C
- Density
- 1.47±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
- form
- Solid
- pka
- 13.58±0.40(Predicted)
- color
- White to yellow
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
H315Causes skin irritation
H319Causes serious eye irritation
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
N-Bromosuccinimide Price
- Product number
- API0012335
- Product name
- PRINOXODAN
- Purity
- 95.00%
- Packaging
- 5MG
- Price
- $499.39
- Updated
- 2021/12/16
- Product number
- CS-7332
- Product name
- Prinoxodan
- Purity
- 95.58%
- Packaging
- 1mg
- Price
- $650
- Updated
- 2021/12/16
- Product number
- CSN21810
- Product name
- Prinoxodan
- Packaging
- 25mg
- Price
- $3498
- Updated
- 2021/12/16
- Product number
- CSN21810
- Product name
- Prinoxodan
- Packaging
- 1mg
- Price
- $605
- Updated
- 2021/12/16
Prinoxodan Chemical Properties,Usage,Production
Uses
Cardiotonic.
in vivo
Prinoxodan (RG W-2938) is a new nonglycoside, noncatecholamine cardiotonic/vasodilator agent is examined in vivo in anesthetized and conscious dogs. Prinoxodan 30-300 μg/kg administered intravenously (i.v.) to anesthetized dogs increases contractile force while decreasing arterial pressure and total peripheral resistance (TPR) in a dose-related manner. Heart rate (HR) is only slightly increased, and aortic flow is not appreciably altered. A single oral dose of Prinoxodan 0.3 mg/kg administered to conscious chronically instrumented dogs produces a marked and sustained increase in contractility 15-240 min after treatment while only slightly increasing HR. The effects of Prinoxodan 30-300 μg/kg, i.v. are studied in a mecamylamine-propranolol-induced model of heart failure. Prinoxodan effectively reverses the drug-induced heart failure by increasing myocardial contractility and decreasing arterial pressure while only slightly affecting HR[2].
Prinoxodan Preparation Products And Raw materials
Raw materials
Preparation Products
Prinoxodan Suppliers
- Tel
- --
- Fax
- --
- enquiry@leancare.co.uk
- Country
- United Kingdom
- ProdList
- 6446
- Advantage
- 42